{"success":true,"data":{"pressRelease":{"id":"140338","rtpr_id":"nPreTw4wka-20260910","ticker":"AFXG","exchange":"XETRA","all_tickers":["AFXG"],"title":"ZEISS announces commercial availability of bitoric hydrophobic monofocal IOL - the ZEISS AT LUCIA toric 721P","author":"PR Newswire","published_at":"2026-09-10T12:00:15.836Z","article_body":"ZEISS announces commercial availability of bitoric hydrophobic monofocal IOL -\nthe ZEISS AT LUCIA toric 721P\nPR Newswire\n\nJENA, Germany, Sept. 10, 2026\n\nLaunching at ESCRS in London, the world's first bitoric hydrophobic monofocal\nintraocular lens with a non-constant asphericity profile design expands the\nZEISS LUCIA Family to treat cataracts while simultaneously correcting\nastigmatism.\n\nJENA, Germany, Sept. 10, 2026 /PRNewswire/ -- ZEISS Medical Technology\nannounced today the commercial availability of the ZEISS AT LUCIA toric 721P\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4770809-1&h=264715617&u=https%3A%2F%2Fwww.zeiss.com%2Fat-lucia-toric&a=ZEISS+AT+LUCIA+toric+721P),\nthe world's first hydrophobic monofocal toric intraocular lens (IOL) with a\nbitoric optic combined with a unique asphericity design. The LUCIA(®) from\nZEISS is the only hydrophobic monofocal IOL family featuring a non-constant\nasphericity profile design (ZEISS Optic). Built to perform independently of\nindividual eye conditions, the ZEISS LUCIA Family takes into account\nvariations in pupil size, corneal spherical aberration, and natural lens\nposition to offer consistent, reliable outcomes in real‑world conditions.\n\n\n\nOfficially launching at the European Society of Cataract and Refractive\nSurgeons (ESCRS) congress\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4770809-1&h=4136859903&u=https%3A%2F%2Fwww.zeiss.com%2Fmeditec%2Fen%2Fnews-events%2Fevents%2Fescrs-2026.html&a=European+Society+of+Cataract+and+Refractive+Surgeons+(ESCRS)+congress) in\nLondon from Sept. 11 – 14, the ZEISS AT LUCIA toric 721P IOL is CE marked\nand now commercially available in select European countries, including\nGermany, Italy, Spain, Portugal, and France.\n\n\"ZEISS once again demonstrates to the market our expertise in optics with a\nhuge leap forward for our IOL offerings. Our broader portfolio will provide\nsurgeons around the world with more options to reach a higher level of patient\nsatisfaction,\" says Andreas Völker, Head of the Ophthalmology Strategic\nBusiness Unit, ZEISS Medical Technology.\n\n\"Providing high reliability and proven lens platform stability, the ZEISS AT\nLUCIA toric 721P is a game changer, enabling surgeons to elevate their\nastigmatism management workflow,\" says Frank Seitzinger, Head of Business\nSector Surgery Anterior Segment, ZEISS Medical Technology.\n\nCelebrating an industry-first innovation at ESCRS\n\nAt ESCRS, ZEISS will mark the launch of its new ZEISS AT LUCIA toric 721P IOL\nwith a celebration in the ZEISS booth C.100 in the South Event Hall on\nSaturday, Sept. 12, from 10:00 – 11:00 AM BST. Attendees will hear from\nsurgeons who participated in early clinical evaluations with the IOL and who\nwill share first-hand insights from their use. Participating surgeons include\nProf. Gerd Auffarth from Heidelberg University Hospital (Germany), Dr. Andrea\nJaneková from Eye Centre Prague (Czech Republic), Dr. Amin Kassem from\nVärnamo Ögoncenter (Sweden), Dr. Fayyaz Musa from The Eye Doctor Clinic\n(UK), Dr. Helena Noguera from Miranza COI (Spain), Dr. Felix Rombold from\nSüdblick Augenzentren (Germany), and Prof. Sathish Srinivasan from Ayrshire\nEye Clinic (UK), who are also receiving the \"ZEISS AT LUCIA toric Pioneer\nAward\" for their pioneering role in adopting the new IOL technology.\n\nTo read the surgeons' clinical perspectives and takeaways following their\nearly implantations of the ZEISS AT LUCIA toric 721P, visit\nhttps://www.zeiss.com/at-lucia-toric.\n\nNot all products, services or offers are approved or offered in every market\nand approved labeling and instructions may vary from one country to another.\nFor country-specific product information, see the appropriate country website.\nProduct specifications are subject to change in design and scope of delivery\nas a result of ongoing technical development. The statements of the healthcare\nprofessionals reflect only their personal opinions and experiences and do not\nnecessarily reflect the opinion of any institution that they are affiliated\nwith. The healthcare professionals alone are responsible for the content of\ntheir experience reported and any potential resulting infringements. Carl\nZeiss Meditec AG and its affiliates do not have clinical evidence supporting\nthe opinions and statements of the health care professionals nor accept any\nresponsibility or liability of the healthcare professionals' content. The\nhealthcare professionals have a contractual or other financial relationship\nwith Carl Zeiss Meditec AG and its affiliates and have received financial\nsupport.\n\nContact for investors\nSebastian Frericks\nDirector Investor Relations\nCarl Zeiss Meditec AG\nPhone: +49 3641 220 116\nMail: investors.med@zeiss.com\n\nContact for the press\nFrank Smith\nHead of Global Communications \nOphthalmology, Carl Zeiss Meditec Inc.\nPhone: +49 3641 220 331\nMail: press.med@zeiss.com\n\nCompany Profile\n\nCarl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the TecDAX and\nSDAx of the German stock exchange, is one of the world's leading medical\ntechnology companies. The Company supplies innovative technologies and\napplication-oriented solutions designed to help doctors improve the quality of\nlife of their patients. The Company offers complete solutions, including\nimplants and consumables, to diagnose and treat eye diseases. The Company\ncreates innovative visualization solutions in the field of microsurgery. With\n5,784 employees worldwide, the Group generated revenue of €2,228m in fiscal\nyear 2024/25 (to 30 September).\n\nThe Group's head office is located in Jena, Germany, and it has subsidiaries\nin Germany and abroad; more than 50 percent of its employees are based in the\nUSA, Japan, Spain and France. The Center for Application and Research (CARIn)\nin Bangalore, India and the Carl Zeiss Innovations Center for Research and\nDevelopment in Shanghai, China, strengthen the Company's presence in these\nrapidly developing economies. Around 39 percent of Carl Zeiss Meditec AG's\nshares are in free float. Approx. 59 percent are held by Carl Zeiss AG, one of\nthe world's leading groups in the optical and optoelectronic industries.\n\nFor further information visit: www.zeiss.com/med\n\n\n\nView original content to download\nmultimedia:https://www.prnewswire.co.uk/news-releases/zeiss-announces-commercial-availability-of-bitoric-hydrophobic-monofocal-iol---the-zeiss-at-lucia-toric-721p-302874676.html\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1985099/ZEISS-AT-LUCIA-toric-721P-IOL.jpg?id=OA2940317\nhttps://mmx.prnewswire.com/media/MS780231/ZEISS-v1-Logo.jpg?id=OA2940318\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPreTw4wka-20260910","title":"ZEISS announces commercial availability of bitoric hydrophobic monofocal IOL - the ZEISS AT LUCIA toric 721P","author":"PR Newswire","ticker":"AFXG","created":"2026-09-10T12:00:15.836Z","tickers":["AFXG"],"exchange":"XETRA","article_body":"ZEISS announces commercial availability of bitoric hydrophobic monofocal IOL -\nthe ZEISS AT LUCIA toric 721P\nPR Newswire\n\nJENA, Germany, Sept. 10, 2026\n\nLaunching at ESCRS in London, the world's first bitoric hydrophobic monofocal\nintraocular lens with a non-constant asphericity profile design expands the\nZEISS LUCIA Family to treat cataracts while simultaneously correcting\nastigmatism.\n\nJENA, Germany, Sept. 10, 2026 /PRNewswire/ -- ZEISS Medical Technology\nannounced today the commercial availability of the ZEISS AT LUCIA toric 721P\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4770809-1&h=264715617&u=https%3A%2F%2Fwww.zeiss.com%2Fat-lucia-toric&a=ZEISS+AT+LUCIA+toric+721P),\nthe world's first hydrophobic monofocal toric intraocular lens (IOL) with a\nbitoric optic combined with a unique asphericity design. The LUCIA(®) from\nZEISS is the only hydrophobic monofocal IOL family featuring a non-constant\nasphericity profile design (ZEISS Optic). Built to perform independently of\nindividual eye conditions, the ZEISS LUCIA Family takes into account\nvariations in pupil size, corneal spherical aberration, and natural lens\nposition to offer consistent, reliable outcomes in real‑world conditions.\n\n\n\nOfficially launching at the European Society of Cataract and Refractive\nSurgeons (ESCRS) congress\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4770809-1&h=4136859903&u=https%3A%2F%2Fwww.zeiss.com%2Fmeditec%2Fen%2Fnews-events%2Fevents%2Fescrs-2026.html&a=European+Society+of+Cataract+and+Refractive+Surgeons+(ESCRS)+congress) in\nLondon from Sept. 11 – 14, the ZEISS AT LUCIA toric 721P IOL is CE marked\nand now commercially available in select European countries, including\nGermany, Italy, Spain, Portugal, and France.\n\n\"ZEISS once again demonstrates to the market our expertise in optics with a\nhuge leap forward for our IOL offerings. Our broader portfolio will provide\nsurgeons around the world with more options to reach a higher level of patient\nsatisfaction,\" says Andreas Völker, Head of the Ophthalmology Strategic\nBusiness Unit, ZEISS Medical Technology.\n\n\"Providing high reliability and proven lens platform stability, the ZEISS AT\nLUCIA toric 721P is a game changer, enabling surgeons to elevate their\nastigmatism management workflow,\" says Frank Seitzinger, Head of Business\nSector Surgery Anterior Segment, ZEISS Medical Technology.\n\nCelebrating an industry-first innovation at ESCRS\n\nAt ESCRS, ZEISS will mark the launch of its new ZEISS AT LUCIA toric 721P IOL\nwith a celebration in the ZEISS booth C.100 in the South Event Hall on\nSaturday, Sept. 12, from 10:00 – 11:00 AM BST. Attendees will hear from\nsurgeons who participated in early clinical evaluations with the IOL and who\nwill share first-hand insights from their use. Participating surgeons include\nProf. Gerd Auffarth from Heidelberg University Hospital (Germany), Dr. Andrea\nJaneková from Eye Centre Prague (Czech Republic), Dr. Amin Kassem from\nVärnamo Ögoncenter (Sweden), Dr. Fayyaz Musa from The Eye Doctor Clinic\n(UK), Dr. Helena Noguera from Miranza COI (Spain), Dr. Felix Rombold from\nSüdblick Augenzentren (Germany), and Prof. Sathish Srinivasan from Ayrshire\nEye Clinic (UK), who are also receiving the \"ZEISS AT LUCIA toric Pioneer\nAward\" for their pioneering role in adopting the new IOL technology.\n\nTo read the surgeons' clinical perspectives and takeaways following their\nearly implantations of the ZEISS AT LUCIA toric 721P, visit\nhttps://www.zeiss.com/at-lucia-toric.\n\nNot all products, services or offers are approved or offered in every market\nand approved labeling and instructions may vary from one country to another.\nFor country-specific product information, see the appropriate country website.\nProduct specifications are subject to change in design and scope of delivery\nas a result of ongoing technical development. The statements of the healthcare\nprofessionals reflect only their personal opinions and experiences and do not\nnecessarily reflect the opinion of any institution that they are affiliated\nwith. The healthcare professionals alone are responsible for the content of\ntheir experience reported and any potential resulting infringements. Carl\nZeiss Meditec AG and its affiliates do not have clinical evidence supporting\nthe opinions and statements of the health care professionals nor accept any\nresponsibility or liability of the healthcare professionals' content. The\nhealthcare professionals have a contractual or other financial relationship\nwith Carl Zeiss Meditec AG and its affiliates and have received financial\nsupport.\n\nContact for investors\nSebastian Frericks\nDirector Investor Relations\nCarl Zeiss Meditec AG\nPhone: +49 3641 220 116\nMail: investors.med@zeiss.com\n\nContact for the press\nFrank Smith\nHead of Global Communications \nOphthalmology, Carl Zeiss Meditec Inc.\nPhone: +49 3641 220 331\nMail: press.med@zeiss.com\n\nCompany Profile\n\nCarl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the TecDAX and\nSDAx of the German stock exchange, is one of the world's leading medical\ntechnology companies. The Company supplies innovative technologies and\napplication-oriented solutions designed to help doctors improve the quality of\nlife of their patients. The Company offers complete solutions, including\nimplants and consumables, to diagnose and treat eye diseases. The Company\ncreates innovative visualization solutions in the field of microsurgery. With\n5,784 employees worldwide, the Group generated revenue of €2,228m in fiscal\nyear 2024/25 (to 30 September).\n\nThe Group's head office is located in Jena, Germany, and it has subsidiaries\nin Germany and abroad; more than 50 percent of its employees are based in the\nUSA, Japan, Spain and France. The Center for Application and Research (CARIn)\nin Bangalore, India and the Carl Zeiss Innovations Center for Research and\nDevelopment in Shanghai, China, strengthen the Company's presence in these\nrapidly developing economies. Around 39 percent of Carl Zeiss Meditec AG's\nshares are in free float. Approx. 59 percent are held by Carl Zeiss AG, one of\nthe world's leading groups in the optical and optoelectronic industries.\n\nFor further information visit: www.zeiss.com/med\n\n\n\nView original content to download\nmultimedia:https://www.prnewswire.co.uk/news-releases/zeiss-announces-commercial-availability-of-bitoric-hydrophobic-monofocal-iol---the-zeiss-at-lucia-toric-721p-302874676.html\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1985099/ZEISS-AT-LUCIA-toric-721P-IOL.jpg?id=OA2940317\nhttps://mmx.prnewswire.com/media/MS780231/ZEISS-v1-Logo.jpg?id=OA2940318\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-09-10T12:00:15.908331738Z","server_sent_at_ms":1789041615908},"received_at":"2026-09-10T12:00:16.055Z","source_url":null},"analysis":{"id":"129161","press_release_id":"140338","analysis_json":{"industry":{"label":"Health Care Equipment","sector":"Health Care"},"redFlags":["launched with CE mark only — no US/FDA availability indicated","endorsing surgeons have contractual or financial relationships with Carl Zeiss Meditec AG and received financial support, per the release's own disclaimer","clinical support limited to early clinical evaluations; company explicitly disclaims clinical evidence for surgeon statements"],"eventType":"product_launch","narrative":"ZEISS Medical Technology announced commercial availability of the ZEISS AT LUCIA toric 721P, described as the world's first bitoric hydrophobic monofocal intraocular lens with a non-constant asphericity profile design.\n\nThe CE-marked lens is officially launching at the ESCRS congress in London (Sept. 11–14) and is now available in select European countries: Germany, Italy, Spain, Portugal, and France, treating cataracts while simultaneously correcting astigmatism.\n\nThe launch expands the LUCIA hydrophobic monofocal IOL family and is supported by seven European surgeons who participated in early clinical evaluations and are receiving the company's 'AT LUCIA toric Pioneer Award' at the congress.\n\nThe underlying issuer, Carl Zeiss Meditec AG (ISIN DE0005313704), generated €2,228m in fiscal 2024/25 revenue with 5,784 employees; the announcement is a routine portfolio addition rather than a near-term financial catalyst.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"World-first bitoric IOL hits select EU markets at ESCRS — incremental premium-portfolio expansion for ZEISS ophthalmology, not a near-term financial catalyst."},"keyFigures":{"revenue":"€2,228m","customDimensions":{"congress":"ESCRS, London, Sept. 11–14, 2026","launch_markets":["Germany","Italy","Spain","Portugal","France"],"revenue_period":"fiscal year 2024/25 (to 30 September), per company profile","regulatory_status":"CE marked","employees_worldwide":5784}},"quotedText":"ZEISS once again demonstrates to the market our expertise in optics with a\nhuge leap forward for our IOL offerings","namedEntities":{"people":[{"name":"Andreas Völker","role":"Head of the Ophthalmology Strategic Business Unit, ZEISS Medical Technology"},{"name":"Frank Seitzinger","role":"Head of Business Sector Surgery Anterior Segment, ZEISS Medical Technology"},{"name":"Prof. Gerd Auffarth","role":"surgeon, Heidelberg University Hospital (Germany); early clinical evaluator and Pioneer Award recipient"},{"name":"Dr. Andrea Janeková","role":"surgeon, Eye Centre Prague (Czech Republic); early clinical evaluator and Pioneer Award recipient"},{"name":"Dr. Amin Kassem","role":"surgeon, Värnamo Ögoncenter (Sweden); early clinical evaluator and Pioneer Award recipient"},{"name":"Dr. Fayyaz Musa","role":"surgeon, The Eye Doctor Clinic (UK); early clinical evaluator and Pioneer Award recipient"},{"name":"Dr. Helena Noguera","role":"surgeon, Miranza COI (Spain); early clinical evaluator and Pioneer Award recipient"},{"name":"Dr. Felix Rombold","role":"surgeon, Südblick Augenzentren (Germany); early clinical evaluator and Pioneer Award recipient"},{"name":"Prof. Sathish Srinivasan","role":"surgeon, Ayrshire Eye Clinic (UK); early clinical evaluator and Pioneer Award recipient"}],"products":["ZEISS AT LUCIA toric 721P","ZEISS LUCIA Family"],"companies":[{"name":"Carl Zeiss Meditec AG","relationship":"filer/underlying issuer (TecDAX/SDAX listed, ISIN DE0005313704)"},{"name":"ZEISS Medical Technology","relationship":"operating unit announcing the launch"},{"name":"Carl Zeiss AG","relationship":"majority shareholder (~59% of Carl Zeiss Meditec AG)"},{"name":"European Society of Cataract and Refractive Surgeons (ESCRS)","relationship":"congress hosting the product launch"}],"dollarAmounts":[{"amount":"€2,228m","context":"Carl Zeiss Meditec AG revenue in fiscal year 2024/25 (to 30 September), stated in company profile boilerplate"}]},"materialImpact":{"score":2,"reasoning":"Commercial availability of the ZEISS AT LUCIA toric 721P — billed as the world's first bitoric hydrophobic monofocal IOL — is a genuine portfolio expansion for the ophthalmology business, but it is a routine launch announcement limited to select European markets with no revenue, guidance, or regulatory catalyst attached."},"tickerRelevance":{"others":[],"primary":"AFXG"},"globalImportance":20,"audienceRelevance":12,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mid-cap, TecDAX/SDAX listed","eventGravity":"routine commercial product launch","regulatoryPath":"CE mark; no US approval stated","geographicScope":"select European markets only","brandRecognition":"ZEISS household optics brand but niche medtech audience"}},"event_type":"product_launch","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"ZEISS Medical Technology announced commercial availability of the ZEISS AT LUCIA toric 721P, described as the world's first bitoric hydrophobic monofocal intraocular lens with a non-constant asphericity profile design.\n\nThe CE-marked lens is officially launching at the ESCRS congress in London (Sept. 11–14) and is now available in select European countries: Germany, Italy, Spain, Portugal, and France, treating cataracts while simultaneously correcting astigmatism.\n\nThe launch expands the LUCIA hydrophobic monofocal IOL family and is supported by seven European surgeons who participated in early clinical evaluations and are receiving the company's 'AT LUCIA toric Pioneer Award' at the congress.\n\nThe underlying issuer, Carl Zeiss Meditec AG (ISIN DE0005313704), generated €2,228m in fiscal 2024/25 revenue with 5,784 employees; the announcement is a routine portfolio addition rather than a near-term financial catalyst.","key_figures":{"revenue":"€2,228m","customDimensions":{"congress":"ESCRS, London, Sept. 11–14, 2026","launch_markets":["Germany","Italy","Spain","Portugal","France"],"revenue_period":"fiscal year 2024/25 (to 30 September), per company profile","regulatory_status":"CE marked","employees_worldwide":5784}},"named_entities":{"people":[{"name":"Andreas Völker","role":"Head of the Ophthalmology Strategic Business Unit, ZEISS Medical Technology"},{"name":"Frank Seitzinger","role":"Head of Business Sector Surgery Anterior Segment, ZEISS Medical Technology"},{"name":"Prof. Gerd Auffarth","role":"surgeon, Heidelberg University Hospital (Germany); early clinical evaluator and Pioneer Award recipient"},{"name":"Dr. Andrea Janeková","role":"surgeon, Eye Centre Prague (Czech Republic); early clinical evaluator and Pioneer Award recipient"},{"name":"Dr. Amin Kassem","role":"surgeon, Värnamo Ögoncenter (Sweden); early clinical evaluator and Pioneer Award recipient"},{"name":"Dr. Fayyaz Musa","role":"surgeon, The Eye Doctor Clinic (UK); early clinical evaluator and Pioneer Award recipient"},{"name":"Dr. Helena Noguera","role":"surgeon, Miranza COI (Spain); early clinical evaluator and Pioneer Award recipient"},{"name":"Dr. Felix Rombold","role":"surgeon, Südblick Augenzentren (Germany); early clinical evaluator and Pioneer Award recipient"},{"name":"Prof. Sathish Srinivasan","role":"surgeon, Ayrshire Eye Clinic (UK); early clinical evaluator and Pioneer Award recipient"}],"products":["ZEISS AT LUCIA toric 721P","ZEISS LUCIA Family"],"companies":[{"name":"Carl Zeiss Meditec AG","relationship":"filer/underlying issuer (TecDAX/SDAX listed, ISIN DE0005313704)"},{"name":"ZEISS Medical Technology","relationship":"operating unit announcing the launch"},{"name":"Carl Zeiss AG","relationship":"majority shareholder (~59% of Carl Zeiss Meditec AG)"},{"name":"European Society of Cataract and Refractive Surgeons (ESCRS)","relationship":"congress hosting the product launch"}],"dollarAmounts":[{"amount":"€2,228m","context":"Carl Zeiss Meditec AG revenue in fiscal year 2024/25 (to 30 September), stated in company profile boilerplate"}]},"model_name":"glm-5.3-flash","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-10T12:03:52.229Z","global_importance":20,"audience_relevance":12,"importance_components":{"tickerTier":"mid-cap, TecDAX/SDAX listed","eventGravity":"routine commercial product launch","regulatoryPath":"CE mark; no US approval stated","geographicScope":"select European markets only","brandRecognition":"ZEISS household optics brand but niche medtech audience"}},"durationMs":56546,"modelName":"glm-5.3-flash"}}